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Aim: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D)
achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as
weight gain, hypoglycaemia and gastrointestinal (GI) side effects.
Materials and methods: Data from the phase IIIa SUSTAIN 1 to 5 clinical trials were analysed.
Participants had inadequately controlled T2D and were drug-naïve (SUSTAIN 1) or on a range of
background treatments (SUSTAIN 2 to 5). The main protocol-specified composite endpoint was
the proportion of participants achieving HbA1c <53 mmol/mol (7.0%) at end of treatment
(30 or 56 weeks) without weight gain and with no severe or blood glucose (BG)-confirmed
symptomatic hypoglycaemia. A post hoc composite endpoint was the proportion of participants
achieving the primary composite endpoint without moderate or severe GI adverse events (AEs).
Results: Across the SUSTAIN trials 1 to 5, 3918 participants with T2D were randomized to
once-weekly subcutaneous semaglutide 0.5 mg, 1.0 mg, or comparators (placebo, sitagliptin
100 mg, exenatide extended release 2.0 mg or insulin glargine). The proportion of participants
achieving HbA1c <53 mmol/mol (7.0%) with no weight gain and no severe/BG-confirmed symp-
tomatic hypoglycaemia was 47% to 66% (semaglutide 0.5 mg) and 57% to 74% (semaglutide
1.0 mg) vs 7% to 19% (placebo) and 16% to 29% (active comparators; all P < .0001). More par-
ticipants achieved the primary composite endpoint with no moderate or severe GI AEs with
semaglutide vs comparators (all P < .0001).
Conclusion: Semaglutide helped more people with T2D achieve HbA1c targets than did compar-
ators in the SUSTAIN 1 to 5 trials, while avoiding unwanted outcomes such as weight gain,
hypoglycaemia and GI side effects.
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1 | INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease characterized by insulin
resistance and a progressive decline in β-cell function.1 Initial manage-
ment of T2D involves lifestyle changes and monotherapy with metfor-
min.1,2 Often, however, as glycaemic control deteriorates,
combination therapy with other oral antidiabetic drugs (OADs) is
required, with or without injectable therapies such as insulin and
glucagon-like peptide-1 receptor agonists (GLP-1RAs).1,2
The optimum treatment for T2D should involve patient-oriented
treatment goals that extend beyond glycated haemoglobin (HbA1c)
reduction alone, such as minimizing the risk of unwanted effects,
including hypoglycaemia and weight gain.3,4
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Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regu-
lates food intake and improves glycaemia in a blood glucose (BG)-
dependent manner.5 GLP-1RAs are effective at reducing HbA1c, body
weight and inducing satiety.1,6 Unlike therapy with insulin and sulphony-
lureas, GLP-1RAs act by inducing glucose-dependent insulin secretion
and are associated with a low risk of hypoglycaemia and weight gain.1,6–8
GLP-1RAs are generally well tolerated,1 although gastrointestinal
(GI) adverse events (AEs) are commonly observed across the class.2,9
Semaglutide (Novo Nordisk, Bagsværd, Denmark) is a novel GLP-1
analogue recently approved by the US Food and Drug Administration
for the treatment of T2D. Its amino acid sequence is 94% homologous
to that of native GLP-1,10 and it has a half-life of ~1 week, which makes
it appropriate for once-weekly subcutaneous (s.c.) administration.10,11
SUSTAIN (Semaglutide Unabated Sustainability in Treatment of
Type 2 Diabetes) is a global phase III clinical trial programme, designed
to evaluate the efficacy and safety of once-weekly s.c. semaglutide
across a range of people with T2D, from those who are drug-naïve to
those receiving OADs and/or insulin.12–17
Across the SUSTAIN trials, significantly more semaglutide-treated
participants achieved HbA1c targets versus comparators, as well as clin-
ically relevant reductions in body weight and a generally low risk of
hypoglycaemia.12–17 In the SUSTAIN 6 trial, semaglutide also showed a
26% cardiovascular risk reduction vs placebo in participants with T2D,
as measured by the composite endpoint of cardiovascular death, non-
fatal myocardial infarction or non-fatal stroke.17 The most common AEs
experienced with semaglutide across the SUSTAIN programme were GI
in nature.12–17 The SUSTAIN 7 trial evaluated once-weekly semaglutide
vs once-weekly dulaglutide in people with T2D18; however, data from
SUSTAIN 7 were not available at the time of this analysis.
In the present study, data from the SUSTAIN 1 to 5 trials12–16 were
analysed to evaluate the proportion of people with T2D achieving clini-
cally relevant HbA1c targets with semaglutide while avoiding unwanted
effects such as weight gain, hypoglycaemia and GI side effects.
2 | METHODS
2.1 | Trial design
The designs of the SUSTAIN 1 to 5 trials (NCT02054897,
NCT01930188, NCT01885208, NCT02128932 and NCT02305381)
have previously been reported in full12–16 and are summarized in
Table 1. Briefly, adults with T2D were randomized to treatment with
semaglutide or comparators for 30 or 56 weeks (Table 1). Compara-
tors included placebo, sitagliptin, exenatide extended release (ER) and
insulin glargine (IGlar).
Semaglutide s.c. 0.5 and 1.0 mg doses were administered in all
SUSTAIN trials except for SUSTAIN 3, in which only the 1.0 mg dose
was administered. The two semaglutide maintenance doses were
administered once weekly. Participants were followed throughout the
planned treatment period, irrespective of treatment adherence. In all
SUSTAIN trials, semaglutide-treated participants followed a fixed
dose-escalation regimen. The semaglutide 0.5 mg maintenance dose
was reached after 4 weeks of semaglutide 0.25 mg once weekly, and
the semaglutide 1.0 mg maintenance dose was reached after 8 weeks:
4 weeks of semaglutide 0.25 mg once weekly, followed by 4 weeks of
0.5 mg once weekly.
Key prespecified endpoints were similar across the SUSTAIN 1 to
5 trials.12–16 For all trials, the primary endpoint was change in HbA1c
from baseline to end of treatment (30 or 56 weeks); the confirmatory
secondary endpoint was change in body weight from baseline to end
of treatment (30 or 56 weeks). Data from SUSTAIN 617 were not
included in the present analysis because of the different design of this
trial compared with others in the SUSTAIN programme; the SUSTAIN
1 to 5 trials were efficacy trials that sought to assess the maximum
treatment effects of semaglutide vs comparators, whereas SUSTAIN
6 was designed to assess the safety of semaglutide in people with
T2D who were at high cardiovascular risk.
2.2 | Study population
Key inclusion and exclusion criteria were generally comparable across
trials. Participants in the SUSTAIN 1 to 5 trials were aged ≥18 years
and diagnosed with T2D, and had baseline HbA1c <53 mmol/mol
(7.0%) to 86 mmol/mol (10.0%) (SUSTAIN 1, 4 and 5) or <53 mmol/
mol (7.0%) to 91 mmol/mol (10.5%).
The main exclusion criteria were history of chronic or idiopathic
acute pancreatitis, known proliferative retinopathy or maculopathy
requiring acute treatment, and baseline estimated glomerular filtration
rate (eGFR) <30 mL/min/1.73 m2 (SUSTAIN 1, 4 and 5) or <60 mL/
min/1.73 m2 (SUSTAIN 2 and 3).
The SUSTAIN 1 to 5 trials included participants at various stages
of their diabetes treatment: drug-naïve (SUSTAIN 1); on metformin
and/or thiazolidinediones (SUSTAIN 2); on 1 to 2 OADs comprising
either metformin, thiazolidinediones and/or sulphonylureas (SUSTAIN
3); on metformin with or without sulphonylureas (SUSTAIN 4); or on
basal insulin with or without metformin (SUSTAIN 5; Table 1). The
main between-trial differences related to pre-existing treatments, if
any, at screening.12–16
All trials were conducted in compliance with the International Con-
ference on Harmonization Good Clinical Practice guidelines and the
Declaration of Helsinki.19 The protocols were approved by local ethics
committees and institutional review boards. Written informed consent
was obtained from all participants before trial commencement.
2.3 | Study endpoints and assessments
The primary, prespecified, composite endpoint in the present analysis was
the proportion of participants from all five trials achieving HbA1c
<53 mmol/mol (7.0%) at the end of treatment (30 or 56 weeks), without
weight gain and with no severe or BG-confirmed symptomatic hypogly-
caemia. The secondary, post hoc composite endpoint was the proportion
of participants achieving the primary composite endpoint without moder-
ate or severe GI AEs. Other endpoints included proportions of participants
achieving HbA1c <53 mmol/mol (7.0%) with either no body weight gain,
no moderate or severe GI AEs, no severe or BG-confirmed hypoglycaemia,
no severe hypoglycaemia, or no BG-confirmed hypoglycaemia.
Severe or BG-confirmed symptomatic hypoglycaemia was defined
as an episode that is considered severe according to the American
Diabetes Association classification,20 or BG-confirmed by a plasma
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glucose value <3.1 mmol/L (56 mg/dL) with symptoms consistent
with hypoglycaemia. No weight gain was defined as strictly no posi-
tive change from baseline in body weight at the end of treatment.
2.4 | Analyses and statistical methods
The analyses reported in the present paper were performed on all ran-
domized and treated participants (full analysis set) using on-treatment
data without rescue medication. To avoid potential confounding of ini-
tiation of antidiabetic rescue therapies on efficacy endpoints, data col-
lected after initiation of antidiabetic rescue therapies were excluded.
Endpoints were analysed using separate logistic regression
models, with treatment, trial-specific stratification and country as
fixed factors, and baseline values of HbA1c and body weight (where
applicable) as covariates. Before analysis, missing HbA1c data were
imputed from separate mixed models for repeated measurements,
with treatment, trial-specific stratification and country and parameter-
specific baseline value, all nested within visit.
3 | RESULTS
3.1 | Participants in the SUSTAIN 1 to 5 trials
Across the SUSTAIN 1 to 5 trials, 3918 participants with T2D were
randomized to once-weekly s.c. semaglutide 0.5, 1.0 mg, or compara-
tors. A total of 3899 (>99%) were exposed to an investigational prod-
uct and 3565 (>90%) participants completed the trials (Table 2).
Discontinuation rates with semaglutide were generally consistent
across SUSTAIN 1 to 5. In individual trials, discontinuation rates were
higher with semaglutide vs placebo (SUSTAIN 1 and 5), sitagliptin
(SUSTAIN 2) and insulin glargine (SUSTAIN 4; Table 2). Discontinuation
rates were similar between semaglutide and exenatide ER in SUSTAIN
3 (Table 2). Rescue medication was administered in 99 semaglutide-
treated and 185 comparator-treated participants (total of 284). The
types of rescue medication administered are summarized in Table S1.
Most participants requiring rescue medication received metformin, sul-
phonylureas or insulin. In the SUSTAIN 2 trial, more participants in the
TABLE 2 Participant disposition and baseline characteristics in the SUSTAIN 1 to 5 trials
SUSTAIN 1:
Semaglutide vs
placebo 30 weeks
SUSTAIN 2:
Semaglutide vs
sitagliptin 100 mg
56 weeks
SUSTAIN 3: Semaglutide
vs exenatide ER 2.0 mg
56 weeks
SUSTAIN 4:
Semaglutide
vs IGlar
30 weeks
SUSTAIN 5: Semaglutide
add-on to insulin vs
placebo 30 weeks
Participant disposition, N (%)
Randomized 388 1231 813 1089 397
Exposed 387 (99.7) 1225 (99.5) 809 (99.5) 1082 (99.4) 396 (99.7)
Trial completers 359 (92.5) 1163 (94.5) 743 (91.4) 1020 (93.7) 380 (95.7)
Premature treatment discontinuation
Semaglutide 0.5 mg 17 (13.3) 53 (13.0) N/A 49 (13.5) 14 (10.6)
Semaglutide 1.0 mg 16 (12.3) 61 (14.9) 82 (20.3) 55 (15.3) 16 (12.2)
Comparator 14 (10.9) 32 (7.9) 85 (21.0) 26 (7.2) 13 (9.8)
Participants administered rescue medication
Semaglutide 0.5 mg 6 (4.7) 25 (6.1) N/A 14 (3.9) 3 (2.3)
Semaglutide 1.0 mg 6 (4.6) 10 (2.4) 29 (7.2) 9 (2.5) 1 (0.8)
Comparator 27 (20.9) 85 (20.9) 48 (11.9) 5 (1.4) 21 (15.8)
Baseline characteristics, mean (SD)
Age, y 53.7 (11.3) 55.1 (10.0) 56.6 (10.7) 56.5 (10.4) 58.8 (10.1)
Male gender, % 54.3 50.6 55.3 53.0 56.1
Diabetes duration,
years
4.2 (5.5) 6.6 (5.1) 9.2 (6.3) 8.6 (6.3) 13.3 (7.8)
Body weight, kg 91.9 (23.8) 89.5 (20.3) 95.8 (21.5) 93.5 (21.8) 91.7 (21.0)
BMI, kg/m2 32.9 (7.7) 32.5 (6.2) 33.8 (6.7) 33.0 (6.5) 32.2 (6.2)
HbA1c, % 8.1 (0.9) 8.1 (0.9) 8.3 (1.0) 8.2 (0.9) 8.4 (0.8)
HbA1c, mmol/mol 64.5 (9.3) 64.8 (10.1) 67.7 (10.4) 65.8 (9.7) 67.9 (9.2)
FPG, mg/dL 175.7 (48.2) 169.4 (40.7) 189.0 (48.7) 175.3 (51.2) 155.9 (53.7)
FPG, mmol/L 9.7 (2.7) 9.4 (2.3) 10.5 (2.7) 9.7 (2.8) 8.6 (3.0)
PPG incrementa,
mg/dL
45.3 (39.2) 51.0 (37.6) 39.7 (33.5) 43.4 (35.1) 55.5 (43.1)
PPG incrementa,
mmol/L
2.5 (2.2) 2.8 (2.1) 2.2 (1.9) 2.4 (1.9) 3.1 (2.4)
Abbreviations: BMI, body mass index; ER, extended release; FPG, fasting plasma glucose; IGlar, insulin glargine; N, number of participants; PPG, postpran-
dial glucose
a PPG increment based on the 7-point (SUSTAIN 1, 2, 3, 5) or 8-point (SUSTAIN 4) self-measured blood glucose profile. Trial completer refers to those par-
ticipants who attended the follow-up visit.
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comparator arm received sulphonylureas than in the semaglutide arms.
In both the SUSTAIN 2 and 5 trials, more participants in the compara-
tor arm initiated insulin or intensified their existing background insulin
as rescue medication than in the semaglutide arms.
Overall, participant baseline characteristics within trials were simi-
lar across treatment groups (Table 2), with any differences among tri-
als reflecting the eligibility criteria. There were differences among the
trials in diabetes duration, indicative of the varying intensity of anti-
diabetic treatments received by the participants with T2D.
3.2 | Primary composite endpoint
The proportion of participants achieving the prespecified primary
composite endpoint of HbA1c <53 mmol/mol (7.0%) at end of treat-
ment without weight gain and with no severe or BG-confirmed symp-
tomatic hypoglycaemia was 47% to 66% with semaglutide 0.5 mg and
57% to 74% with semaglutide 1.0 mg, vs 7% to 19% with placebo and
16% to 29% with active comparators (Figure 1). Significantly more
participants treated with semaglutide 0.5 and 1.0 mg once weekly
achieved this composite endpoint vs comparators (all P < .0001;
Figure 1).
3.3 | Post hoc composite endpoint
In the post hoc analysis, the proportion of participants achieving the
composite endpoint of HbA1c <53 mmol/mol (7.0%) at end of
treatment without weight gain, with no severe or BG-confirmed
symptomatic hypoglycaemia, and with no moderate or severe GI AEs
was 40% to 55% with semaglutide 0.5 mg and 46% to 64% with
semaglutide 1.0 mg, vs 7% to 19% with placebo and 14% to 25% with
active comparators (Figure 2). Significantly more semaglutide-treated
participants achieved this composite endpoint vs comparators (all
P < .0001; Figure 2).
3.4 | Analyses of individual components of
composite endpoints
Results for the individual components of composite endpoints were
mostly consistent with the findings for the primary and secondary
composite endpoints. In SUSTAIN 1 to 5, the proportion of
participants achieving HbA1c <53 mmol/mol (7.0%) was 58% to 74%
with semaglutide 0.5 mg and 67% to 79% with semaglutide 1.0 mg, vs
11% to 25% with placebo and 36% to 40% with active comparators
(Figure 3A). Significantly more participants achieved HbA1c targets of
<53 mmol/mol (7.0%) with semaglutide 0.5 and 1.0 mg than with
comparators (all P < .0001; Figure 3A). The proportion of participants
with no weight gain was 82% to 89% with semaglutide 0.5 mg and
86% to 97% with semaglutide 1.0 mg, vs 64% to 66% with placebo
and 34% to 69% with active comparators (all P ≤ .0006; Figure 3B).
The proportion of participants with no severe or BG-confirmed symp-
tomatic hypoglycaemia was 92% to 100% with semaglutide 0.5 mg
and 89% to 100% with semaglutide 1.0 mg, vs 95% to 100% with
FIGURE 1 Participants achieving glycated haemoglobin (HbA1c) <53 mmol/mol (7.0%) without weight gain and with no severe or blood glucose-
confirmed symptomatic hypoglycaemia. *P < .0001 vs comparator. On-treatment without rescue medication data. The binary endpoint was
analysed using a logistic regression with treatment, trial-specific stratification and country as fixed factors, and baseline HbA1c and body weight
as covariates. Missing data were imputed from a mixed model for repeated measurements for change from baseline in which post-baseline data
were analysed, with treatment, trial-specific stratification and country as fixed factors, and baseline value as covariate, all nested within visit.
CI, confidence interval; ER, extended release; IGlar, insulin glargine; MET, metformin; n, number of participants contributing to analysis; N/A, not
applicable; OAD, oral antidiabetic drug; OR, odds ratio; SU, sulphonylurea; TZD, thiazolidinedione
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placebo and 89% to 99% with active comparators (P < .008 for sema-
glutide 0.5 and 1.0 mg vs IGlar in SUSTAIN 4; Figure 3C).
The proportion of participants with no moderate or severe GI AEs
was lower with semaglutide than with comparators. The proportion of
participants with no moderate/severe GI AEs was 84% to 92% with
semaglutide 0.5 mg and 82% to 89% with semaglutide 1.0 mg, vs 97%
with placebo and 89% to 95% with active comparators (P < 0.01 for
all comparisons except semaglutide 0.5 mg vs placebo in SUSTAIN 5;
Figure 3D).
The proportion of participants achieving HbA1c <53 mmol/mol
(7.0%) with no body weight gain ranged from 49% to 66% with sema-
glutide 0.5 mg, and 62% to 77% with semaglutide 1.0 mg, vs 8% to
19% with placebo and 17% to 31% with active comparators. Signifi-
cantly more participants achieved HbA1c targets of <53 mmol/mol
(7.0%) and no weight gain with semaglutide 0.5 and 1.0 mg than with
comparators (P < .0001 for all comparisons; Figure S1A). The propor-
tion of participants achieving HbA1c of <53 mmol/mol (7.0%) with no
moderate or severe GI AEs was 51% to 62% with semaglutide 0.5 mg,
and 54% to 69% with semaglutide 1.0 mg, vs 10% to 25% with pla-
cebo and 34% to 36% with active comparators (P ≤ .0002 for all com-
parisons; Figure S1B).
The proportion of participants achieving HbA1c <53 mmol/mol
(7.0%) without severe or BG-confirmed hypoglycaemia was 54% to
74% with semaglutide 0.5 mg, and 61% to 78% with semaglutide
1.0 mg, vs 10% to 25% with placebo and 34% to 37% with active
comparators (P < .0001 for all comparisons; Figure S1C).
The proportion of participants achieving HbA1c <53 mmol/mol (7.0%)
with no severe hypoglycaemia (as defined by the American Diabetes
Association) ranged from 57% to 74% with semaglutide 0.5 mg, 67%
to 78% with semaglutide 1.0 mg, vs 11% to 25% with placebo and
36% to 40% with comparators (P < .0001 for all comparisons;
Figure S2A). The proportion of participants achieving HbA1c
<53 mmol/mol (7.0%) with no BG-confirmed hypoglycaemia was 54%
to 74% with semaglutide 0.5 mg, 61% to 78% with semaglutide
1.0 mg, vs 10% to 25% with placebo and 34% to 37% with active
comparators (P < .0001 for all comparisons; Figure S2B).
4 | DISCUSSION
When attempting to achieve adequate glycaemic control, it is impor-
tant to also consider the risk of unwanted outcomes such as hypogly-
caemia and weight gain.1–4,8 The present analysis of combined data
from the SUSTAIN clinical trial programme evaluated the proportion
of participants who achieved the HbA1c target of <53 mmol/mol
(7.0%) with no weight gain, no severe or BG-confirmed symptomatic
hypoglycaemia, and no moderate or severe GI AEs. The cumulative
sample size of >3900 participants represents a diverse population of
participants with T2D.
Across the SUSTAIN 1 to 5 trials, approximately half to two-thirds
of participants who received semaglutide 0.5 mg achieved an HbA1c
concentration < 53 mmol/mol (7.0%) without weight gain and with
no severe or BG-confirmed symptomatic hypoglycaemia. Up to three-
FIGURE 2 Participants achieving glycated haemoglobin (HbA1c) <53 mmol/mol (7.0%) without weight gain, with no severe or blood glucose-
confirmed symptomatic hypoglycaemia, and with no moderate or severe gastrointestinal adverse events. *P < .0001 vs comparator.
On-treatment without rescue medication data. The binary endpoint was analysed using a logistic regression with treatment, trial-specific
stratification, and country as fixed factors and baseline HbA1c and body weight as covariates. Missing data were imputed from a mixed model for
repeated measurements for change from baseline in which post-baseline data were analysed with treatment, trial-specific stratification and
country as fixed factors, and baseline value as covariate, all nested within visit. CI, confidence interval; ER, extended release; IGlar, insulin
glargine; MET, metformin; n, number of participants contributing to analyses; N/A, not applicable; OAD, oral antidiabetic drug; OR, odds ratio;
SU, sulphonylurea; TZD, thiazolidinedione
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quarters of participants achieved this outcome with semaglutide
1.0 mg. With both semaglutide doses, significantly more participants
achieved this composite endpoint vs those receiving comparators.
The overall difference was mostly driven by larger proportions of
participants achieving HbA1c <53 mmol/mol (7.0%) as well as by the
proportions of participants experiencing no weight gain. The propor-
tions of participants achieving HbA1c <53 mmol/mol (7.0%) with only
one component of “no body weight gain”, “no moderate or severe GI
AEs”, or “no severe or BG-confirmed symptomatic hypoglycaemia”,
were each significantly greater with semaglutide 0.5 and 1.0 mg vs
comparators. The proportions of participants receiving semaglutide
achieving HbA1c <53 mmol/mol (7.0%) with no hypoglycaemia were
consistent regardless of the definition of hypoglycaemia used (severe,
BG-confirmed symptomatic, or severe or BG-confirmed symptomatic).
These findings are generally consistent with those from other
studies and compare favourably with published data for other GLP-
1RAs.1,6,7,21 For instance, a meta-analysis of seven clinical trials in par-
ticipants with T2D showed that 32% to 40% of participants receiving
liraglutide achieved HbA1c <53 mmol/mol (7.0%) concentrations
without weight gain or hypoglycaemia, vs 8% for placebo and 8% to
25% for comparators (exenatide, IGlar, sitagliptin, sulphonylureas or
thiazolidinedione).21 A similar analysis of the AWARD clinical trial pro-
gramme showed that participants with T2D receiving dulaglutide were
equally likely to achieve HbA1c <53 mmol/mol (7.0%) without weight
gain or hypoglycaemia as those receiving liraglutide.22 Furthermore,
the SUSTAIN 7 trial showed that participants with T2D who were
treated with once-weekly semaglutide experienced superior reduc-
tions in HbA1c and body weight, in comparison with those treated
with dulaglutide.18
Across the SUSTAIN 1 to 5 trials, semaglutide was well tolerated,
with a similar safety profile to that of other GLP-1RAs.12–16,23,24 The
most common AEs leading to discontinuation of semaglutide were GI
in nature and, overall, most cases of GI AEs were mild or moderate
and of a short duration.12–16,23,24 GI AEs are commonly observed
across the GLP-1RA class,2,9 and may affect treatment outcomes in
the real-world setting. In SUSTAIN 1 to 5, >80% of participants expe-
rienced no GI AEs, regardless of their randomized treatment; however,
the proportion of participants with no GI AEs was lower with sema-
glutide, vs comparators, except in the semaglutide 0.5 mg group in
SUSTAIN 5. With semaglutide 0.5 or 1.0 mg, approximately half of the
participants achieved HbA1c concentrations <53 mmol/mol (7.0%)
without weight gain, severe or BG-confirmed symptomatic hypogly-
caemia, or moderate/severe GI AEs, which was significantly more than
participants treated with comparators. The overall effect for the post
hoc composite endpoint was mostly driven by the proportion of
participants achieving HbA1c <53 mmol/mol (7.0%) and those
experiencing no weight gain. Similar analyses with liraglutide and dula-
glutide have not examined the role of GI AEs in participants achieving
HbA1c <53 mmol/mol (7.0%) without weight gain or severe or BG-
confirmed symptomatic hypoglycaemia.21,22
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FIGURE 3 Proportion of participants achieving glycated haemoglobin (HbA1c) <53 mmol/mol (7.0%) (A), with no weight gain (B), no severe or
BG-confirmed symptomatic hypoglycaemia (C) or no moderate or severe gastrointestinal adverse events (D). *P < .0001; **P < .001; ***P < .01
vs comparator. On-treatment without rescue medication data. The binary endpoint was analysed using a logistic regression with treatment, trial-
specific stratification and country as fixed factors, and baseline HbA1c and body weight as covariates. Missing data were imputed from a mixed
model for repeated measurements for change from baseline in which post-baseline data were analysed with treatment, trial-specific stratification
and country as fixed factors, and baseline value as covariate, all nested within visit. ER, extended release; IGlar, insulin glargine; MET, metformin;
n, number of participants contributing to analysis; OAD, oral antidiabetic drug; SU, sulphonylurea; TZD, thiazolidinedione
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Both semaglutide 0.5 and 1.0 mg have demonstrated consistently
superior efficacy in terms of glycaemic control. Treatment with sema-
glutide 0.5 or 1.0 mg has also previously been shown to result in supe-
rior weight reduction, from baseline values, vs comparators.12–16 This
effect was generally greater with semaglutide 1.0 than with 0.5 mg.
A potential criticism of the present analyses of the SUSTAIN 1 to
5 trials concerns the analyses of individual components of the prespe-
cified and post hoc composite endpoints. When evaluated in isolation,
each component may differ in their clinical importance; therefore, one
should consider the validity of giving each component equal weight
when combining them into composite endpoints. Conversely, a clear
advantage of the present analyses is the number of participants
involved in the SUSTAIN 1 to 5 trials. The trials involved >3900
participants with T2D, and various stages of the treatment and the
disease were represented, from treatment-naïve participants receiving
monotherapy to those on insulin and other background therapies. Fur-
thermore, each trial independently recruited sufficient participants to
allow meaningful evaluations between semaglutide and a number of
relevant comparators. Trials varied in duration (30 weeks for SUS-
TAIN 1, 4 and 5; 56 weeks for SUSTAIN 2 and 3), which may poten-
tially have affected the proportions of participants achieving the
composite endpoint; however, with the 56-week trials, large propor-
tions of participants achieved both composite endpoints, suggesting
that the effects of semaglutide are sustainable over the long term.
Overall, these results indicate a consistency in the effect of sema-
glutide 0.5 and 1.0 mg across a broad range of participants with T2D,
including drug-naïve participants and those on background therapies
consisting of OADs and/or insulin.
In conclusion, across the overall populations with T2D participat-
ing in the SUSTAIN 1 to 5 trials, significantly more participants
achieved the HbA1c target of <53 mmol/mol (7.0%) without weight
gain and with no hypoglycaemia when treated with semaglutide than
with comparators. More participants benefitted from treatment with
semaglutide vs comparators even when the composite endpoint was
expanded to include the absence of moderate or severe GI AEs as a
component. Semaglutide helped more people with T2D achieve
HbA1c targets vs comparators in the SUSTAIN 1 to 5 trials, while
avoiding unwanted outcomes such as weight gain, hypoglycaemia,
and GI side effects.
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